TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Invivyd ( (IVVD) ) has shared an update.
On November 17, 2025, Invivyd, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. for a public offering of 44,000,000 shares of common stock and pre-funded warrants for 6,000,000 shares, raising approximately $117.2 million. The proceeds will support the commercial preparedness for VYD2311, ongoing research and development, and other corporate purposes, potentially impacting the company’s market position and stakeholders.
The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary integrated technology platform to develop and adapt antibodies, and it received emergency use authorization from the U.S. FDA in March 2024 for a monoclonal antibody in its pipeline.
Average Trading Volume: 10,536,959
Technical Sentiment Signal: Buy
Current Market Cap: $662.1M
Learn more about IVVD stock on TipRanks’ Stock Analysis page.